Approval of Biocon Biologics Yesintek recommended by EMA Committee Ruchika Sharma16 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
Ustekinumab Offers Potential in Protecting Beta-Cells for Adolescents with Type 1 Diabetes, Study Suggests Nidhi Srivastava29 Aug 2024 8:00 PM ISTUK: A multicenter, double-blind, randomized phase 2 trial of Ustekinumab for adolescents with type 1 diabetes was featured in an article in Nature...
Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, Japan Ruchika Sharma29 Aug 2024 12:30 PM ISTBangalore: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, announced today that the...
Sandoz unveils biosimilar Pyzchiva across Europe to treat chronic inflammatory diseases Ruchika Sharma28 July 2024 10:30 AM ISTBasel: Sandoz has announced the launch of Pyzchiva (ustekinumab) across Europe. Pyzchiva, developed and registered by Samsung Bioepis, a ustekinumab...
Sandoz confirms European Commission nod of Pyzchiva Ruchika Sharma23 April 2024 11:54 AM ISTBasel: Sandoz has announced that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab) developed...
Guselkumab Shows Superior Efficacy Over Ustekinumab for treatment of Psoriatic Arthritis: Study Dr Riya Dave13 March 2024 11:45 PM ISTPsoriatic arthritis is a chronic inflammatory condition that affects joints and skin, often causing pain, swelling, and skin lesions. Biologic...
Sandoz gets exclusive rights to commercialize biosimilar SB17 ustekinumab in US, Canada, EEA, Switzerland and UK Ruchika Sharma11 Sept 2023 1:30 PM ISTThe reference medicine Stelara (ustekinumab) is a monoclonal antibody medication to interleukin (IL)-12/23 for the treatment of autoimmune disorders...
Intas Pharma marketing authorization application for proposed biosimilar of Stelara accepted by EMA Ruchika Sharma15 July 2023 11:00 AM ISTDMB-3115 is a proposed biosimilar to Stelara which is a blockbuster drug developed by Janssen Biotech Inc. for plaque psoriasis, psoriatic arthritis,...
Aurobindo Pharma arm CuraTeQ Biologics to commercialize proposed biosimilar to Stelara Ruchika Sharma8 July 2023 12:00 PM ISTCuraTeQ intends to file this product in India and Emerging Markets as early as in 2024 and the regulated markets filing is expected to begin in 2026.
Teva, Alvotech secure US license date for AVT04, a proposed biosimilar to Stelara Ruchika Sharma13 Jun 2023 1:30 PM ISTIceland: Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and...
Ustekinumab effective long term treatment for active Psoriatic Arthritis: SUSTAIN Study data Dr Supreeth D R16 Nov 2022 8:00 PM ISTPsoriatic arthritis (PsA) is a chronic, progressive disease that places a significant burden on patients and healthcare systems. The SUSTAIN study...
Biocon Biologics collaborates with Yoshindo to commercialize bUstekinumab, bDenosumab in Japan Ruchika Sharma17 Oct 2022 2:30 PM ISTDenosumab, a biosimilar referencing Prolia, is a monoclonal antibody for the treatment of osteoporosis.
